Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study

Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study IntroductionMigraine usually ameliorates after menopause. However, 10–29% of women still experience migraine attacks after menopause, especially if menopause is surgical. The use of monoclonal antibodies against the calcitonin gene-related peptide (CGRP) is changing the landscape of migraine treatment. This study aims to explore the effectiveness and safety of anti-CGRP monoclonal antibodies in women in menopause.MethodsWomen affected by either migraine or chronic migraine and treated with an anti-CGRP monoclonal antibody for up to 1 year. Visits were scheduled every 3 months.ResultsWomen in menopause displayed a similar response compared to women of childbearing age. Among women in menopause, the women experiencing surgical menopause seemed to exhibit a similar response compared to the ones experiencing physiological menopause. Erenumab and galcanezumab displayed similar effectiveness in women in menopause. No serious adverse events were registered.DiscussionThe effectiveness of anti-CGRP monoclonal antibodies is almost the same between women in menopause and women of childbearing age, without appreciable differences between the different antibodies. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Neurologica Belgica Springer Journals

Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study

Download PDF
9 pages

Loading next page...
 
/lp/springer-journals/monoclonal-anti-cgrp-antibodies-in-post-menopausal-women-a-real-life-eDN00G4fd9
Publisher
Springer Journals
Copyright
Copyright © The Author(s) under exclusive licence to Belgian Neurological Society 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
ISSN
0300-9009
eISSN
2240-2993
DOI
10.1007/s13760-023-02190-5
Publisher site
See Article on Publisher Site

Abstract

IntroductionMigraine usually ameliorates after menopause. However, 10–29% of women still experience migraine attacks after menopause, especially if menopause is surgical. The use of monoclonal antibodies against the calcitonin gene-related peptide (CGRP) is changing the landscape of migraine treatment. This study aims to explore the effectiveness and safety of anti-CGRP monoclonal antibodies in women in menopause.MethodsWomen affected by either migraine or chronic migraine and treated with an anti-CGRP monoclonal antibody for up to 1 year. Visits were scheduled every 3 months.ResultsWomen in menopause displayed a similar response compared to women of childbearing age. Among women in menopause, the women experiencing surgical menopause seemed to exhibit a similar response compared to the ones experiencing physiological menopause. Erenumab and galcanezumab displayed similar effectiveness in women in menopause. No serious adverse events were registered.DiscussionThe effectiveness of anti-CGRP monoclonal antibodies is almost the same between women in menopause and women of childbearing age, without appreciable differences between the different antibodies.

Journal

Acta Neurologica Belgica – Springer Journals

Published: Jun 1, 2023

Keywords: Migraine; Menopause; Calcitonin gene-related peptide; Monoclonal antibodies

References

  • The international classification of headache disorders, 3rd edition
  • Migraine prevalence by age and sex in the United States: a life-span study
    Victor, TW; Hu, X; Campbell, JC; Buse, DC; Lipton, RB
  • Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen
    MacGregor, EA; Frith, A; Ellis, J; Aspinall, L; Hackshaw, A
  • The complex relationship between estrogen and migraines: a scoping review
    Reddy, N; Desai, MN; Schoenbrunner, A; Schneeberger, S; Janis, JE
  • Perimenopause and menopause are associated with high frequency headache in women with migraine: results of the American migraine prevalence and prevention study
    Martin, VT; Pavlovic, J; Fanning, KM; Buse, DC; Reed, ML; Lipton, RB
  • Changes in migraine before and after menopause in Japanese climacteric women
    Makita, K; Inagaki, M; Kitamura, S; Tatsuoka, Y
  • Headaches in middle-aged women during menopausal transition: a headache clinic-based study
    Oh, K; Jung, KY; Choi, JY; Seo, WK; Park, KW
  • Migraine in menopausal women: a systematic review
    Ripa, P; Ornello, R; Degan, D; Tiseo, C; Stewart, J; Pistoia, F; Carolei, A; Sacco, S
  • The efficacy and safety of venlafaxine in the prophylaxis of migraine
    Ozyalcin, SN; Talu, GK; Kiziltan, E; Yucel, B; Ertas, M; Disci, R
  • The effect of paroxetine on the reduction of migraine frequency is independent of its anxiolytic effect
    Park, HJ; Lee, ST; Shim, JY; Kim, B; Hwang, SH; Kim, SH; Park, JE; Park, JH; Jung, SH; Ahn, JY; Chu, K; Kim, M
  • Efficacy of escitalopram for hot flashes in healthy menopausal woman: a randomized controlled trial
    Freeman, EW; Guthrie, KA; Caan, B; Sternfeld, B; Cohen, LS; Joffe, H; Carpenter, JS; Anderson, GL; Larson, JC; Ensrud, KE; Reed, SD; Newton, KM; Sherman, S; Sammel, MD; LaCroix, AZ
  • Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults
    Linde, M; Mulleners, WM; Chronicle, EP; McCrory, DC
  • FDA approval of paroxetine for menopausal hot flushes
    Orleans, RJ; Li, L; Kim, MJ; Guo, J; Sobhan, M; Soule, L; Joffe, HV
  • Hormonal management of migraine at menopause
    Nappi, R; Sances, G; Detaddei, S; Ornati, A; Chiovato, L; Polatti, F
  • Therapeutic novelties in migraine: new drugs, new hope?
    Do, TP; Guo, S; Ashina, M
  • Validation of the headache impact test (HIT-6™) across episodic and chronic migraine
    Yang, M; Rendas-Baum, R; Varon, SF; Kosinski, M
  • The headache-attributed lost time (HALT) indices: measures of burden for clinical management and population-based research
    Steiner, TJ; Lipton, RB
  • The migraine disability assessment (MIDAS) questionnaire: translation and reliability of the Italian version
    D’Amico, D; Mosconi, P; Genco, S; Usai, S; Prudenzano, AM; Grazzi, L; Leone, M; Puca, FM; Bussone, G
  • Role of CGRP in migraine
    Edvinsson, L
  • Changes of plasma calcitonin gene-related peptide levels in postmenopausal women
    Valentini, A; Petraglia, F; De Vita, D; Nappi, C; Margutti, A; degli Uberti, EC; Genazzani, AR
  • Plasma levels of CGRP during a 2-h infusion of VIP in healthy volunteers and patients with migraine: an exploratory study
    Pellesi, L; Al-Karagholi, MAM; De Icco, R; Chaudhry, BA; Lopez, CL; Snellman, J; Hannibal, J; Amin, FM; Ashina, M
  • The PACAP pathway is independent of CGRP in mouse models of migraine: possible new drug target?
    Ernstsen, C; Christensen, SL; Rasmussen, RH; Nielsen, BS; Jansen-Olesen, I; Olesen, J; Kristenson, DM
  • Effect of adrenomedullin on migraine-like attacks in patients with migraine: a randomized crossover study
    Ghanizada, H; Al-Kaaragholi, MAM; Arngrim, N; Mørch-Rasmussen, M; Walker, CS; Hay, DL; Ashina, M
  • Amylin analog pramlintide induces migraine-like attacks in patients
    Ghanizada, H; Al-Karagholi, MAM; Walker, CS; Arngrim, N; Rees, T; Petersen, J; Siow, A; Mørch-Rasmussen, M; Tan, S; O’Carroll, SJ; Harris, P; Skovgaard, LT; Jørgensen, NR; Brimble, M; Waite, JS; Rea, BJ; Sowers, LP; Russo, AF; Hay, DL; Ashina, M
  • Is calcitonin gene-related peptide a reliable biochemical marker of migraine?
    Tesfay, B; Karlsson, WK; Moreno, RD; Hay, DL; Hougaard, A
  • Gender aspects of CGRP in migraine
    Labastida-Ramìrez, A; Rubio-Beltràn, E; Villalòn, CM; MaassenVanDenBrink, A
  • Increased concentration of circulating calcitonin gene related peptide during normal human pregnancy
    Stevenson, JC; Macdonald, DW; Warren, RC; Booker, MW; Whitehead, MI
  • Estrogen receptors α, β and GPER in the CNS and trigeminal system-molecular and functional aspects
    Warfringe, K; Krause, DN; Maddahi, A; Edvinsson, JCA; Edvinsson, L; Haanes, KA
  • Reduced trigeminovascular cyclicity in patients with menstrually related migraine
    Ibrahimi, K; van Oosterhout, WPJ; Van Dorp, W; Danser, AHJ; Garrelds, IM; Kushner, SA; Lesaffre, EMEH; Terwindt, GM; Ferrari, MD; van der Meiracker, AH; MaassenVanDenBrink, A
  • Migraine, menopause and hormone replacement therapy
    MacGregor, EA
  • Effects of estrogen on the serotoninergic system and calcitonin gene-related peptide in trigeminal ganglia of rats
    Aggarwal, M; Puri, V; Puri, S
  • Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy
    Benshushan, A; Rojansky, N; Chaviv, M; Arbel-Alon, S; Benmeir, A; Imbar, T; Brzezinski, A
  • Concentrations of calcitonin gene-related peptide and neuropeptide Y in plasma increase during flushes in postmenopausal women
    Wyon, YA; Spetz, AC; Theodorsson, GE; Hammar, ML
  • Migraine in the post-menopausal period is associated with higher levels of mood disorders, disability, and more menopausal symptoms
    Carturan, P; Scorcine, C; Fragoso, YD
  • Predictors of response to erenumab after 12 months of treatment
    Baraldi, C; Lo Castro, F; Cainazzo, MM; Pani, L; Guerzoni, S
  • Patterns of migraine in postmenopausal women: a systematic review
    Ornello, R; Caponnetto, V; Frattale, I; Sacco, S
  • Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier
    Noseda, R; Schain, AJ; Melo-Carrillo, A; Tien, J; Stratton, J; Mai, F; Strassman, AM; Burstein, R
  • Mechanisms of pain modulation by sex hormones in migraine
    Gupta, S; McCarson, KE; Welch, KMA; Berman, NEJ
  • Deficiency of female sex hormones augments PGE2 and CGRP levels within midbrain periaqueductal gray
    Wang, D; Zhao, J; Wang, J; Li, J; Yu, S; Guo, X
  • Up-regulation of calcitonin gene-related peptide receptors underlying elevation of skin temperature in ovariectomized rats
    Noguchi, M; Ikarashi, Y; Yuzurihara, M; Mizoguchi, K; Kurauchi, K; Chen, JT; Ishige, A
  • Pharmacokinetic-pharmacodynamic relationship of erenumab (AMG334) and capsaicin-induced dermal blood flow in healthy and migraine subjects
    Vu, T; Ma, P; Chen, JS; de Hoon, J; Van Hecken, A; Yan, L; Wu, LS; Hamilton, L; Vargas, G
  • Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis
    Drellia, K; Kokoti, L; Deligianni, CI; Papadopoulos, D; Mitsikostas, DD
  • Understanding CGRP and cardiovascular risk
    Rubio-Beltran, E; Maassen van den Brink, A
  • Menopause and cardiovacsular disease: the evidence
    Rosano, GMC; Vitale, C; Marazzi, G; Volterrani, M